BIIB News

Biogen shares fall on JP Morgan downgrade (San Diego Daily Transcript via Yahoo! News) - Shares of Biogen Idec Inc. (Nasdaq: BIIB), which houses its Research & Corporate Campus in San Diego, fell Monday after JP Morgan cut its rating on the stock, saying the multiple sclerosis drug Tysabri could continue facing challenges in 2009 while the company lacks any catalysts to drive new revenue.

Seven Summits Research Releases Comments on T, ICE, SNDK, NOC, and BIIB (PR Newswire via Yahoo! Finance) - Seven Summits Research releases NewsBites on key stocks.

Analysts' Upgrades, Downgrades: Verizon (TheStreet.com) - See who made what calls.

The new year brings a fresh round of merger-and-acquisition news (Schaeffers Research) - Today's Early Edge includes an acquisition for MasterCard Incorporated (MA), an update on Steve Jobs' mysterious weight loss from Apple Inc...( Read More )

This Week's 'Barron's' Roundup (TheStreet.com) - How to play the Treasury bond bubble, picking stocks with Laszlo Birinyi and more.

Biotech Mailbag: Cell Thera-Pew-Tics (TheStreet.com) - Investors have a least three huge reasons to avoid this company.

Barron's Profile: View From The Top (CattleNetwork.com) - Many fund managers describe themselves as "bottom-up" stockpickers, meaning they look for undervalued securities with growth potential, regardless of what the economy or market is doing.

First Marblehead, Avid, State Street hit in 2008 (Boston Business Journal) - Although local stocks joined in a broader rally over the last few days of 2008, most nevertheless took a huge pounding over the course of the year. (FMD) (STT) (EMC) (BXP) (BSX) (TJX) (RTN)

Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (Medical News Today) - Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint.

Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis ... (Medical News Today) - Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint.

Quotes and extra info offered through independent providers described on our corporate partner page. S&P 500 quotes provided by Comstock. Historic chart data and daily updates supplied by Commodity Systems. Mutual fund summary and performance furnished by Zacks. Analyst estimates information supplied by StockCharts.Com. All data provided by StockCharts.Com is based exclusively upon research data furnished by outside commentators. We have not studied, and in no way corroborate the validity of the aforementioned information. We and StockCharts.Com will not be liable because of any trade implemented in reliance thereon. All info provided "as is" for educational practices only, not intended for trading purposes or advice. Neither us nor any of the individual suppliers is held liable in regard to any informational mistakes, incompleteness, or postponements, or for any actions implemented in dependence on data incorporated herein. By using our web site, you agree not to redistribute the data obtained therein.

Analyst Calls It "A Stock Pickers Dream Come True" Our Best Selling Software Finds Growth & Momentum With Just 1 Click

How To Buy Low & Sell High Every Time Guaranteed Long Term Strategy Guarantees "Buy Low & Sell High". Learn More

"Precision Entry & Exit Points On Every Stock In Your Portfolio" California Developer Offers Solutions For High Tech Traders.

"The Web's Best Desktop Financial Portal" The smartest traders on the web get all the content they need, without all the ads they don't and its FREE.